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Abstract
The prospect of using neural cell replacement for the treatment of severe enteric neu-
ropathies has seen significant progress in the last decade. The ability to harvest and 
transplant enteric neural crest cells (ENCCs) that functionally integrate within recipi-
ent intestine has recently been confirmed by in vivo murine studies. Although similar 
cells can be harvested from human fetal and postnatal gut, no studies have as yet veri-
fied their functional viability upon in vivo transplantation. We sought to determine 
whether ENCCs harvested from human fetal bowel are capable of engraftment and 
functional integration within recipient intestine following in vivo transplantation into 
postnatal murine colon. Enteric neural crest cells selected and harvested from fetal 
human gut using the neurotrophin receptor p75NTR were lentivirally labeled with 
either GFP or calcium- sensitive GCaMP and transplanted into the hindgut of Rag2−/
γc−/C5−- immunodeficient mice at postnatal day 21. Transplanted intestines were 
assessed immunohistochemically for engraftment and differentiation of donor cells. 
Functional viability and integration with host neuromusculature was assessed using 
calcium imaging. Transplanted human fetal gut- derived ENCC showed engraftment 
within the recipient postnatal colon in 8/15 mice (53.3%). At 4 weeks posttransplanta-
tion, donor cells had spread from the site of transplantation and extended projections 
over distances of 1.2 ± 0.6 mm (n = 5), and differentiated into enteric nervous system 
(ENS) appropriate neurons and glia. These cells formed branching networks located 
with the myenteric plexus. Calcium transients (change in intensity F/F0 = 1.25 ± 0.03; 
15 cells) were recorded in transplanted cells upon stimulation of the recipient endog-
enous ENS demonstrating their viability and establishment of functional connections.
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1  | INTRODUCTION
Enteric neuropathies are a diverse and clinically important range of 
conditions characterized by aberrant or absent propulsive contractile 
activity secondary to loss or malfunction of the enteric nervous sys-
tem (ENS).1–4 Such disorders range from those in which there is a con-
genital or acquired absence of intrinsic ENS (e.g. Hirschsprung disease 
and esophageal achalasia), to conditions such as intestinal pseudo- 
obstruction and slow transit constipation which result from more 
subtle neuronal deficits that remain to be better defined.5–7 Current #These authors contributed equally to the work.
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treatments are unsatisfactory and limited to surgical interventions, 
which are associated with high levels of morbidity and mortality.1 
Alternative therapeutic strategies are required for these conditions.8
The ENS is formed during embryogenesis by migratory neu-
ral crest cells arising in the vagal and sacral regions of the neu-
ral tube (reviewed in Ref. 9). Enteric neural crest cells (ENCC), 
which give rise to enteric neurons, glia, and stem cells, can be 
isolated from both embryonic and postnatal murine intestine.10,11 
Furthermore, upon transplantation, they are able to colonize 
both ganglionic and aganglionic murine bowel in vivo, forming 
neural networks that display functional integration with the host 
neuromusculature.12,13
The potential to develop a clinically applicable cell replacement ther-
apy for enteric neuropathies has been validated by the isolation of ENCC 
from fetal and postnatal human gut8,14–16 To date, human gut- derived 
ENCCs have been transplanted within in vitro models of aganglionosis, 
showing physical integration and differentiation.14,15,17 However, their 
functional integration remains to be demonstrated within a postnatal in 
vivo model. Here, we report the efficient isolation of ENCC from human 
fetal gut and successful engraftment and functional integration follow-
ing in vivo transplantation into immunodeficient murine gut.
2  | MATERIALS AND METHODS
2.1  | Animals
Animals were maintained, and experiments were performed, in accord-
ance with local approvals and the UK Animals (Scientific Procedures) Act 
1986 under license from the Home Office (PPL70/7500). Rag2−/γc−/
C5−- immunodeficient mice, deficient in innate immunity and lacking all 
lymphocytes, were used as recipients for ENCC transplantations.18,19
2.2  | Human cells and tissues
Fetal human gut (age 12–15 weeks) was obtained from the Human 
Developmental Biology Resource, UCL Institute of Child Health, 
London, UK, with informed, written consent and under ethical approv-
al from the Health Research Authority (08/H0712/34+5). Studies 
were performed according to the Declaration of Helsinki. Enteric 
neural crest cells were isolated, sorted, and cultured as described 
previously.14 They generated primary neurospheres after approxi-
mately 1 week, and these were transplanted within 15–30 days.
2.3  | Lentiviral labeling of human ENCC
Lentiviral constructs expressing enhanced green fluorescent protein 
(EGFP)20 and GCaMP (Addgene plasmid 42168:pJMK019, Adam 
Cohen; Addgene, Cambridge, MA, USA) were used to label cells with 
high levels of GFP or a calcium- sensitive GFP construct, respectively. 
Isolation of lentiviral particles and subsequent transduction of cells 
was conducted according to a protocol described previously.20
2.4  | Transplantation of ENCC into gut in vivo
Enteric neural crest cells were transplanted into the distal colon of 
immune- deficient Rag2−/γc−/C5− knockout mice via laparotomy 
(described previously Ref. 13) at weaning (postnatal day 21; n = 15). 
Mice were maintained for 4 weeks posttransplantation before they 
were killed and analyzed.
2.5  | Immunohistochemistry
Transplanted bowel was fixed and analyzed using immunohistochem-
istry as described previously.13 The primary antibodies used were 
mouse TuJ1 (1:1000; Biolegend, London, UK) and rabbit anti- cow 
S100 (1:500; Dako, Ely, Cambridgeshire, UK), and secondary antibod-
ies were anti- mouse and anti- rabbit Alexafluor 568 (1:500; Invitrogen, 
Carlsbad, CA, USA).
Images were acquired on a Zeiss LSM 710 confocal microscope 
(Zeiss, Cambridge, UK) and processed using ImageJ21 and Adobe 
Photoshop CS3 software (Adobe, San Jose, CA, USA).
2.6  | Calcium imaging of transplanted ENCC
Colonic gut samples were prepared as described previously.13 The 
endogenous ENS was stimulated via an electrode placed approximate-
ly 200 μm from the transplanted cells. Changes in the fluorescence 
intensity of GCaMP elicited by calcium transients within transplanted 
cells were then imaged and processed as described previously.13
3  | RESULTS
Fetal human gut tissue was dissociated and ENCC selected by FACS, 
based on the expression of the NCC marker p75 (25.6 ± 2.5% of dis-
sociated cells were p75+ve; n = 3). Enteric neural crest cells were 
transduced with GFP or GCaMP with a labeling efficiency of 92 ± 3% 
Key Points
● ENCCs have been identified as a source for a cell replacement 
therapy in enteric neuropathies. Murine ENCCs are capable of 
colonization and function within mouse bowel in vivo. This 
work investigated the potential of human gut-derived ENCC 
in vivo.
● Upon transplantation, fetal human-derived ENCCs display 
engraftment, spread, extension of projections, differentiation 
towards neurons and glia and functional connectivity with the 
endogenous ENS.
● This is the first report of in vivo transplantation of human gut-
derived ENCC and provides proof-of-concept data for their 
clinical application in cell replacement therapies.
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(n = 5) and 75 ± 14% (n = 5), respectively. Transduced cells maintained 
fluorescence and formed GFP/GCaMP- expressing neurospheres after 
7–10 days in vitro (inset in Fig. 1A).
Human fetal GFP+ or GCaMP+ labeled cells were transplanted, as 
neurospheres, into the distal gut of Rag2−/γc−/C5−- immunodeficient 
mice and were detected up to 8 weeks later in 8/15 guts examined 
F IGURE  1 Transplanted GFP/GCaMP5G+ human fetal p75 sorted gut- derived ENCCs generate functional networks of enteric neurons 
and glia in mouse gut. (Inset in A) p75+ FACS selected human fetal (week 14) gut- derived neurosphere transduced with GFP (green). (A) 
Wholemount gut preparation in which GFP+ transplanted cells (green) project along endogenous TuJ1+ ENS nerve fibers (red). Arrowheads 
indicate the extent of neuronal projections within the myenteric plexus. (B) High- power image of TuJ1+ enteric ganglia (red) showing co- 
localization with GFP+ cell projections (taken from inset 1 in A). (C) High- power image of TuJ1+; GFP+ transplanted cells within a ganglion- 
like structure containing TuJ1+ cells (taken from inset 2 in A). (D) GFP+ transplanted cells (green) co- express the glial marker S100 (red). (E) 
Representative image of transplanted GCaMP5G+ fetal human- derived neurons within Rag2−/γc−/C5− mouse distal colon. Arrows indicate 
neurons from which Ca2+ responses are plotted in (F). (F) Representative traces showing Ca2+ responses recorded as F/F0 from transplanted 
neurons (TP cell) upon stimulation of endogenous neuronal fibers. (G) Transplanted cells and fibers indicated by arrows (equivalent to those in 
E) co- express GFP and the neuronal marker TuJ1. (H) Z- projection of the boxed area in G showing GFP/TuJ1 expressing (yellow) transplanted 
cell bodies (arrowheads) and their projections (arrows) within the endogenous TuJ1 expressing myenteric plexus (red). Inset below shows an 
orthogonal view (orthog.) taken through the entire depth of the boxed region showing transplanted neuronal cell bodies (arrowhead) projecting 
(arrowheads) to the endogenous myenteric plexus (red). DAPI labels nuclei in blue. Scale bar in A inset = 50 μm; A = 100 μm; B and C = 25 μm; 
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(53.3%). GFP expression was strong and facilitated visualization of 
cell bodies and projections posttransplantation. Transplanted ENCCs 
spread and formed both interconnections between cells (Fig. 1A) and 
ganglia- like structures (Fig. 1C) reminiscent of the endogenous ENS.
Four weeks after transplantation, GFP+ cells expressed neuronal 
and glial markers (TuJ1, Fig. 1A–C and S100, Fig. 1D, respectively). Cell 
bodies from transplanted cells were located adjacent to those of endog-
enous neurons (Fig. 1C) and projections from transplanted cells followed 
endogenous ENS fiber tracts of the myenteric plexus, showing physical 
integration within the endogenous network. Projections were visible 
over a distance of 1.2 ± 0.6 mm (n = 5), after 4 weeks (Fig. 1A and B).
GCaMP expression in transplanted cells enabled assessment of 
functional integration within the gut. Spontaneous calcium transients 
(global and vesicular) were observed in ENCC both in vitro and occa-
sionally in transplanted cells within gut preparations ex vivo (data not 
shown). Electrical point stimulation applied to endogenous neuronal 
fibers within the host gut musculature resulted in calcium transients in 
cell bodies and fibers of transplanted GCaMP+ cells (change in intensity 
F/F0 = 1.25 ± 0.03; 15 cells) (Fig. 1E and F and Video S1). Subsequent 
TuJ1 immunohistochemical staining confirmed that GCaMP+ cell bod-
ies and fibers, activated upon stimulation of the endogenous network, 
were neuronal (Fig. 1G). 3D reconstruction of confocal images revealed 
the fine structure of the physical connections of the transplanted 
human- derived GCaMP+ neurons and the endogenous ENS (Fig. 1H).
4  | DISCUSSION
A number of studies using murine cells support the idea of using stem 
cell transplantation for the treatment of enteric neuropathies such as 
Hirschsprung disease.12–14 As a first step to explore the potential of 
human gut- derived ENCC for in vivo transplantation, we sought to study 
fetal enteric neural stem cells. We have previously shown that neuro-
spheres containing such cells are formed faster and with higher efficiency 
than their postnatal counterparts.16 We wished to confirm that commit-
ted human ENCCs sourced early in development retain the potential 
for cell therapy. To this end, we demonstrated that fetal gut- derived 
ENCC can be efficiently isolated from the enteric cell population by sort-
ing for p75 (25.6 ± 2.5%), with a greater efficiency than that achieved 
by ourselves and others for postnatal gut- derived ENCC (5.8 ± 2.8%; D. 
Natarajan, unpublished findings and 4.82; SEM = 1.43%, respectively).22 
These ENCC can be labeled using lentiviral constructs to facilitate subse-
quent cell tracing and functional studies. Human fetal ENCC proved suc-
cessful at colonizing postnatal mouse colon, forming extensive networks 
of neurons and glia, which physically integrated with the endogenous 
ENS. Crucially we showed, for the first time, the functional integration of 
transplanted human gut- derived cells within in vivo gut.
Having confirmed the ability of fetal human gut- derived ENCC 
to functionally colonize the intact ENS, a number of challenges 
remain to be addressed. These include determining whether these 
cells retain functionality and elicit rescue within a model of enter-
ic neuropathic disease, if they are safe to transplant and indeed 
whether they are a viable cell source for use in a therapeutic setting. 
Previously, we reported higher cell engraftment outcomes following 
in vivo transplantation of mouse- derived ENCC (90.3%) in contrast 
to 53.3% in this study. This is likely to reflect both our experience 
that human cells appear somewhat less robust under experimental 
conditions than their mouse counterparts as well as the expected 
inherent variability of human samples utilized in our study (e.g., the 
age and condition of the sample received, gut regions available for 
culture, and genetic variability between samples). There was no 
evidence of host immune response in the examined gut (data not 
shown) to explain the reduced engraftment of human- derived cells.
A recent study by Fattahi et al. reported the transplantation of human 
embryonic stem cells (ESC), differentiated toward an early vagal neural 
crest lineage, in the postnatal colon of a mouse model of Hirschsprung 
Disease in vivo.23 Although the transplanted cells appeared to show 
efficient pan- colonic colonization and were able to rescue the lethal 
phenotype of this model, the authors were unable to comment on the 
mechanism by which rescue may have been elicited and functionality of 
the transplanted cells was not demonstrated.23 Although their work is 
a step toward validation of the use of ESC in enteric neuropathies, ESC 
safety for transplantation, in terms of colonizing off- target locations and 
tumorigenicity, was not addressed. In our study, we successfully har-
vested a cell type already committed to the ENS lineage, theoretically 
reducing the risk of uncontrolled proliferation. This is supported by our 
previous work using mouse- derived ENCC, which provided evidence 
that this cell type is safe to transplant within an in vivo environment.13 
Such safety data must be further extended to human gut- derived ENCC.
Here, we used fetal human gut- derived ENCC as a cell source 
with which to demonstrate the ability of human ENCC to integrate 
functionally with the ENS in vivo. Given concerns regarding the 
sourcing and use of fetal (and embryonic) cells as a therapeutic tool, 
our current studies aim to investigate the capabilities of postnatally 
sourced ENCC within the in vivo environment. We and others have 
demonstrated that ENCC can be sourced from routine mucosal gut 
biopsies of both children and adults.14,24,25 Clinically, these cells 
could benefit from being autologously sourced from minimally inva-
sive procedures, thus circumventing both ethical concerns and any 
requirement for immunosuppression upon transplantation. However, 
several challenges remain to be addressed including optimization of 
protocols to maximize the proliferative capacity of postnatal- derived 
cells, and convincing demonstration of their functional viability.
In conclusion, our findings advance the search for a cell replace-
ment therapy for enteric neuropathies by demonstrating that within 
the context of in vivo transplantation human gut- derived ENCCs are 
able to contribute to the ENS in recipient mouse bowel. Importantly, 
human- derived neurons form structural and functional connections 
with the endogenous ENS and thus are potentially capable of restoring 
function to neuropathic bowel. The data provide proof of concept for 
the in vivo transplantation of human ENCCs.
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